Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.37 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 2/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405367 | 0.82 | PTGDR2 (0.58) | PTGDR2PTGDRALDH1A1RAB9ALMNA | |
| SCHEMBL6410482 | 0.78 | ALDH1A1 (0.46) | ALDH1A1ALDH1A3ALDH3A1RAB9ALMNA | |
| SCHEMBL6405848 | 0.77 | SIGMAR1 (0.45) | PTGDR2ALDH1A1TSHRHTT | |
| SCHEMBL6405527 | 0.75 | ALDH1A1 (0.54) | PTGDR2PTGDRALDH1A1ALDH1A3TSHR | |
| SCHEMBL6407399 | 0.73 | ALDH1A1 (0.56) | PTGDR2PTGDRALDH1A1ALDH1A3PDE4B | |
| SCHEMBL3925300 | 0.72 | PTGDR2 (0.39) | PTGDR2PTGDRALDH1A1ALDH1A3TSHR | |
| SCHEMBL6741417 | 0.71 | ALDH3A1 (0.39) | ALDH1A1ALDH1A3ALDH3A1 | |
| SCHEMBL11292175 | 0.70 | MEN1 (0.43) | ALDH1A1ALDH1A3ALDH3A1RAB9ALMNA | |
| SCHEMBL7262913 | 0.69 | ALDH1A1 (0.36) | PTGDR2PTGDRALDH1A1ALDH1A3TSHR | |
| SCHEMBL7509476 | 0.67 | ALDH1A1 (0.50) | ALDH1A1LMNATSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-6689806-B1 | MODULATING PROTEIN KINASES AND RELATED SIGNAL TRANSDUCTION PATHWAYS | SUGEN, INC. | 2004-02-10 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1165513-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | Sugen, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056709-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | PTGDR2 898/4885PTGDR 886/4885ALDH1A1 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.